Evidence map›Paper›PMID 33922611›Full record

ArticleAntibiotics (Basel, Switzerland)2021

Triphenilphosphonium Analogs of Chloramphenicol as Dual-Acting Antimicrobial and Antiproliferating Agents.

Julia A Pavlova, Zimfira Z Khairullina, Andrey G Tereshchenkov, Pavel A Nazarov, Dmitrii A Lukianov, Inna A Volynkina, Dmitry A Skvortsov, Gennady I Makarov, Etna Abad, Somay Y Murayama and 8 more

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Rhodamine 19 Alkyl Esters as Effective Antibacterial Agents.International journal of molecular sciences · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 3 countries.

Julia A PavlovaDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1, 119991 Moscow, Russia.
Zimfira Z KhairullinaDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1, 119991 Moscow, Russia.ORCID 0000-0002-9136-2060
Andrey G TereshchenkovA.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Leninskie Gory 1, 119992 Moscow, Russia.ORCID 0000-0002-3293-3951
Pavel A NazarovA.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Leninskie Gory 1, 119992 Moscow, Russia.
Dmitrii A LukianovCenter of Life Sciences, Skolkovo Institute of Science and Technology, 143028 Skolkovo, Russia.
Inna A VolynkinaSchool of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119992 Moscow, Russia.
Dmitry A SkvortsovDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1, 119991 Moscow, Russia.
Gennady I MakarovLaboratory of the Multiscale Modeling of Multicomponent Materials, South Ural State University, 454080 Chelyabinsk, Russia.
Etna AbadDepartment of Experimental and Health Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0002-9431-5817
Somay Y MurayamaDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8340, Japan.
Susumu KajiwaraSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Kanagawa 226-8501, Japan.
Alena PaleskavaPetersburg Nuclear Physics Institute, NRC "Kurchatov Institute", 188300 Gatchina, Russia.
Andrey L KonevegaPetersburg Nuclear Physics Institute, NRC "Kurchatov Institute", 188300 Gatchina, Russia.ORCID 0000-0003-0125-7150
Yuri N AntonenkoA.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Leninskie Gory 1, 119992 Moscow, Russia.ORCID 0000-0002-0244-855X
Alex LyakhovichInstitute of Molecular Biology and Biophysics, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia.ORCID 0000-0002-8279-4697
Ilya A OstermanDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1, 119991 Moscow, Russia.ORCID 0000-0001-7748-980X
Alexey A BogdanovDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1, 119991 Moscow, Russia.
Natalia V SumbatyanDepartment of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1, 119991 Moscow, Russia.
Lomonosov Moscow State University · RUPeter the Great St. Petersburg Polytechnic University · RUSkolkovo Institute of Science and Technology · RUMoscow Institute of Physics and Technology · RUNational Institute of Infectious Diseases · JPSouth Ural State University · RUTokyo Institute of Technology · JPUniversitat Pompeu Fabra · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current work, in continuation of our recent research, we synthesized and studied new chimeric compounds, including the ribosome-targeting antibiotic chloramphenicol (CHL) and the membrane-penetrating cation triphenylphosphonium (TPP), which are linked by alkyl groups of different lengths. Using various biochemical assays, we showed that these CAM-Cn-TPP compounds bind to the bacterial ribosome, inhibit protein synthesis in vitro and in vivo in a way similar to that of the parent CHL, and significantly reduce membrane potential. Similar to CAM-C4-TPP, the mode of action of CAM-C10-TPP and CAM-C14-TPP in bacterial ribosomes differs from that of CHL. By simulating the dynamics of CAM-Cn-TPP complexes with bacterial ribosomes, we proposed a possible explanation for the specificity of the action of these analogs in the translation process. CAM-C10-TPP and CAM-C14-TPP more strongly inhibit the growth of the Gram-positive bacteria, as compared to CHL, and suppress some CHL-resistant bacterial strains. Thus, we have shown that TPP derivatives of CHL are dual-acting compounds targeting both the ribosomes and cellular membranes of bacteria. The TPP fragment of CAM-Cn-TPP compounds has an inhibitory effect on bacteria. Moreover, since the mitochondria of eukaryotic cells possess qualities similar to those of their prokaryotic ancestors, we demonstrate the possibility of targeting chemoresistant cancer cells with these compounds.

Indexed as

alkyl(triphenyl)phosphoniumantibiotic activityantiproliferative activitybacterial ribosomechloramphenicolmolecular dynamics simulations

Identifiers

PMID33922611
PMCPMC8145938
OpenAlexW3139599929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.